Who are AMG 386 and Trastuzumab's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amg-386-and-trastuzumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AMG 386 and Trastuzumab — Competitive Intelligence Brief

AMG 386 and Trastuzumab (AMG 386 and Trastuzumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiopoietin-2 inhibitor, HER2/neu receptor antagonist. Area: Oncology.

phase 2 Angiopoietin-2 inhibitor, HER2/neu receptor antagonist Ang-2, HER2/neu Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AMG 386 and Trastuzumab (AMG 386 and Trastuzumab) — QuantumLeap Healthcare Collaborative. AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AMG 386 and Trastuzumab TARGET	AMG 386 and Trastuzumab	QuantumLeap Healthcare Collaborative	phase 2	Angiopoietin-2 inhibitor, HER2/neu receptor antagonist	Ang-2, HER2/neu

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiopoietin-2 inhibitor, HER2/neu receptor antagonist class)

QuantumLeap Healthcare Collaborative · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMG 386 and Trastuzumab — Competitive Intelligence Brief. https://druglandscape.com/ci/amg-386-and-trastuzumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab